Scholar Rock Revenue and Competitors

Boston, MA USA

Location

$358M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Scholar Rock's estimated annual revenue is currently $18.2M per year.(i)
  • Scholar Rock received $47.0M in venture funding in January 2018.
  • Scholar Rock's estimated revenue per employee is $116,667
  • Scholar Rock's total funding is $358M.
  • Scholar Rock's current valuation is $710.2M. (January 2022)

Employee Data

  • Scholar Rock has 156 Employees.(i)
  • Scholar Rock grew their employee count by 30% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M20%N/AN/A
#3
$4.2M278%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M50%N/AN/A
#6
$235M246-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
N/A3776%N/AN/A
#10
$5.3M294%N/AN/A
Add Company

Scholar Rock® is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Scholar Rock is creating a pipeline of novel product candidates with the potential to transform the lives of patients suffering from a wide range of serious diseases, including neuromuscular disorders, cancer, fibrosis and anemia. Scholar Rock's newly elucidated understanding of the molecular mechanisms of growth factor activation enabled it to develop a proprietary platform for the discovery and development of monoclonal antibodies that locally and selectively target these signaling proteins at the cellular level. By developing product candidates that act in the disease microenvironment, the Company intends to avoid the historical challenges associated with inhibiting growth factors for therapeutic effect. Scholar Rock believes its focus on biologically validated growth factors may facilitate a more efficient development path.

keywords:Biotechnology,Healthcare,Healthcare Providers,Pharmaceuticals

$358M

Total Funding

156

Number of Employees

$18.2M

Revenue (est)

30%

Employee Growth %

$710.2M

Valuation

N/A

Accelerator

Scholar Rock's People

NameTitleEmail/Phone
1
SVP, Technical OperationsReveal Email/Phone
2
Chief Human Resources OfficerReveal Email/Phone
3
VP, Apitegromab Program Lead (Spinal Muscular Atrophy)Reveal Email/Phone
4
VP, Finance and ControllerReveal Email/Phone
5
VP, Head BiometricsReveal Email/Phone
6
Senior Patent SpecialistReveal Email/Phone
7
Associate Director, HR OperationsReveal Email/Phone
8
Senior Director, Discovery BiologyReveal Email/Phone
9
Senior Scientist IIReveal Email/Phone
10
General Counsel & Corporate SecretaryReveal Email/Phone

Scholar Rock News

2022-04-19 - Scholar Rock Presents Data Analysis of Multiple Efficacy ...

Scholar Rock is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of...

2022-04-17 - Zacks: Analysts Anticipate Scholar Rock Holding Co ...

Two analysts have made estimates for Scholar Rock's earnings. The highest sales estimate is $33.20 million and the lowest is $33.19 million.

2022-04-13 - -$0.68 Earnings Per Share Expected for Scholar Rock Holding ...

Equities analysts forecast that Scholar Rock Holding Co. (NASDAQ:SRRK – Get Rating) will announce ($0.68) earnings per share (EPS) for the...

2021-09-29 - Scholar Rock : Announces Issuance of U.S. Patent Protecting SRK-181, an Inhibitor of TGF 1 Activation

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 11,130,803, ...

2021-06-14 - SCHOLAR ROCK HOLDING CORPORATION Scholar Rock : Presents TOPAZ Phase 2 Data Showing the Transformative Potential of Apitegromab in Patients with Type 2 and 3 Spinal Muscular Atrophy (SMA) at the 2021 Virtual SMA Research & Clinical Care Meeting

CAMBRIDGE, Mass. - Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, announced an oral presentation of TOPAZ Phase 2 trial results by the lead principal investigator, Thom ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$34M1565%N/A
#2
$17.6M1568%N/A
#3
$38.7M1578%N/A
#4
$15M1580%N/A
#5
$24.9M1596%N/A

Scholar Rock Funding

DateAmountRoundLead InvestorsReference
2014-09-16$20.0MAARCH Venture PartnersArticle
2016-01-05$36.0MBFidelity Management and Research CompanyArticle
2018-01-04$47.0MCInvusArticle